Acelarin: Phase Ib data

Data from 20 evaluable patients with recurrent platinum-resistant ovarian cancer in the open-label, dose-escalation, U.K. Phase

Read the full 166 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE